磷酸雌莫司汀预防促黄体生成素释放激素类似物长效注射疗法中的病情复发
Estramustine phosphate for preventing flare-up in luteinizing hormone-releasing hormone analogue depot therapy.
作者信息
Shimizu T S, Shibata Y, Jinbo H, Satoh J, Yamanaka H
机构信息
Department of Urology, Gunma Cancer Center, Ota, Japan.
出版信息
Eur Urol. 1995;27(3):192-5. doi: 10.1159/000475159.
The usefulness of estramustine phosphate (ECT) for preventing flare-up in goserelin acetate depot therapy for advanced prostate cancer was studied. Pretreatment with ECT 560 mg daily for 3 weeks almost completely prevented the rise in testosterone level seen in goserelin acetate depot therapy and no signs or symptoms of tumor flare were observed. Long-term ECT completely blocked the rise in luteinizing hormone and testosterone level, but ECT at this dosage was likely to cause complications. The administration of ECT 560 mg daily for 3 weeks prior to goserelin acetate depot therapy was considered sufficient to prevent tumor flare, and its effect was considered to be more marked than that of short-term treatment with antiandrogens.
研究了磷酸雌莫司汀（ECT）在醋酸戈舍瑞林长效注射治疗晚期前列腺癌中预防病情恶化的有效性。每日口服560mg ECT进行3周预处理，几乎完全阻止了醋酸戈舍瑞林长效注射治疗中观察到的睾酮水平升高，且未观察到肿瘤病情恶化的体征或症状。长期使用ECT可完全阻断黄体生成素和睾酮水平的升高，但此剂量的ECT可能会引起并发症。在醋酸戈舍瑞林长效注射治疗前3周每日给予560mg ECT被认为足以预防肿瘤病情恶化，且其效果被认为比使用抗雄激素药物进行短期治疗更显著。
Zotero 插件